Dose-finding Study of LFB-R593, A Monoclonal Anti-RhD Antibody, in Healthy RhD Negative Volunteers
Launched by LABORATOIRE FRANÇAIS DE FRACTIONNEMENT ET DE BIOTECHNOLOGIES · Aug 4, 2009
Trial Information
Current as of June 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy RhD-negative volunteers
- • Males and definitively sterile females
- • No prior sensitization to RhD antigen
- Exclusion Criteria:
- • Healthy RhD-positive volunteers
About Laboratoire Français De Fractionnement Et De Biotechnologies
Laboratoire Français de Fractionnement et de Biotechnologies (LFB) is a leading biopharmaceutical company based in France, specializing in the development, production, and commercialization of innovative therapeutic solutions derived from human plasma. With a strong focus on biotechnology, LFB is committed to advancing healthcare through rigorous research and development, ensuring high-quality standards in its manufacturing processes. The organization plays a pivotal role in addressing unmet medical needs, particularly in the fields of immunology, hematology, and critical care, by leveraging its expertise in fractionation and bioprocessing. Through collaborative partnerships and a dedication to scientific excellence, LFB strives to enhance patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Patients applied
Trial Officials
Thomas Kornicke
Principal Investigator
Parexel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials